Glaukos Corporation Common Stock (GKOS)
Stock · NYSE · Health Care
$164.87as of 10/16/2026
Price chart
Active signals
GKOS Signal Track Record
How signals performed across all stocks →What GKOS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +2.2% | 62% | October 8, 2026 |
| Bollinger Band Breakout | 28 | +2.3% | 54% | July 30, 2026 |
| Bollinger Band Breakdown | 17 | +2.2% | 59% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +8.8% | 63% | May 28, 2026 |
| Any 20-session window (baseline) | +3.3% | 61% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The com…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 1,094
- Website
- www.glaukos.com
Fundamentals
- 1-day range
- $163.13$167.28
- Market cap
- $10.09B
- P/E (trailing)
- —
- P/E (forward)
- 314.38
- EPS (trailing)
- $-3.26
- Dividend yield
- —
- Beta
- 0.73
- Avg. volume
- 853.9K
How Glaukos Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Glaukos Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- GKOSGlaukos Corporation Common Stock$164.84▼ 0.46%Market cap $10.09BP/E —$73.16$191.62
- PODDInsulet Corporation Common Stock$141.1▲ 1.68%Market cap $9.65BP/E 25.40$126.4$354.88
- GMEDGlobus Medical Inc. Class A Common Stock$76.71▼ 2.70%Market cap $11.01BP/E 19.14$56.96$101.4
- BAXBaxter International Inc. Common Stock$25.28▼ 1.86%Market cap $13.96BP/E —$15.73$30
- TFXTeleflex Incorporated Common Stock$130.43▲ 1.72%Market cap $6.15BP/E —$100.18$145
- STVNStevanato Group S.p.A. Ordinary Shares$18.9▼ 1.82%Market cap $6.14BP/E 34.82$12.89$27.99
- MMSIMerit Medical Systems Inc. Common Stock$89.2▼ 0.41%Market cap $5.24BP/E 36.22$59.74$94.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GKOS Glaukos Corporation Common Stock | $10.09B | — | $164.84 | ▼ 0.46% | $73.16$191.62 |
| PODD Insulet Corporation Common Stock | $9.65B | 25.40 | $141.1 | ▲ 1.68% | $126.4$354.88 |
| GMED Globus Medical Inc. Class A Common Stock | $11.01B | 19.14 | $76.71 | ▼ 2.70% | $56.96$101.4 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $25.28 | ▼ 1.86% | $15.73$30 |
| TFX Teleflex Incorporated Common Stock | $6.15B | — | $130.43 | ▲ 1.72% | $100.18$145 |
| STVN Stevanato Group S.p.A. Ordinary Shares | $6.14B | 34.82 | $18.9 | ▼ 1.82% | $12.89$27.99 |
| MMSI Merit Medical Systems Inc. Common Stock | $5.24B | 36.22 | $89.2 | ▼ 0.41% | $59.74$94.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BTIG Maintains Buy on Glaukos, Raises Price Target to $205benzinga · 10/12/2026
- Glaukos: The Second J-Code Rewrites The Risk MathSeekingAlpha · 10/9/2026
- Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing DealYahoo · 10/9/2026
- Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye TherapyBenzinga · 10/9/2026
- Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract SurgeryYahoo · 10/9/2026
- Glaukos Announces Topline Results From Its Phase 4 Trial Evaluating iDose TR With Cataract Surgery In Patients With Open-Angle Glaucoma Or Ocular Hypertension; Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority And Clinically Meaningful IOP Reduction Vs Cataract Surgery AloneBenzinga · 10/9/2026
- Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing DealYahoo · 10/8/2026
- Will Three-Year Epioxa Data in Keratoconus Shift Glaukos' (GKOS) Corneal Portfolio Narrative?Yahoo · 10/8/2026
- Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal DiseasesYahoo · 10/8/2026
Insider Activity
Insider Actions →- Tomas Navratil · October 5, 2026 · Sale312 @ $165.6
- Tomas Navratil · October 5, 2026 · Sale327 @ $164.78
- Tomas Navratil · October 5, 2026 · Sale888 @ $163.93
- Tomas Navratil · September 25, 2026 · Sale1.1K @ $154.88
- Tomas Navratil · September 25, 2026 · Sale229 @ $154.24
- Tomas Navratil · September 25, 2026 · Sale136 @ $152.71
- Tomas Navratil · September 25, 2026 · Sale167 @ $151.7
- Tomas Navratil · September 16, 2026 · Sale4 @ $172
- Tomas Navratil · September 16, 2026 · Sale234 @ $170.95
- Tomas Navratil · September 16, 2026 · Sale120 @ $168.38
- Tomas Navratil · September 16, 2026 · Sale460 @ $167.32
- Tomas Navratil · September 16, 2026 · Sale191 @ $166.2
- Tomas Navratil · September 16, 2026 · Sale345 @ $164.6
- Tomas Navratil · September 16, 2026 · Sale103 @ $163.2
- Tomas Navratil · August 28, 2026 · Sale10 @ $182.5
Institutional Ownership
March 31, 2026
- Total shares held
- 54.72M
- Total value held
- $5.78B
- Institutional holders
- 331
- Unknown9.09M
- Unknown5.35M
- Unknown3.37M
- Unknown2.51M
- Unknown2.18M
- Unknown1.61M
- Unknown1.47M
- Unknown1.40M
- Unknown1.38M
- Unknown1.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
GKOS Joins Big Stocks Rising on Wednesday; 10‑Year Gains Highlight
GKOS was among the large stocks that gained on Wednesday, adding to its recent upward momentum. A Benzinga piece noted that a $1,000 investment in GKOS 10 years ago would be worth a substantial amount today, underscoring the company's long‑term growth. These stories highlight both the current price action and the company's historical performance.
GKOS Joins Big Stocks Rising on Wednesday; 10‑Year Gains Highlight. GKOS was among the large stocks that gained on Wednesday, adding to its recent upward momentum. A Benzinga piece noted that a $1,000 investment in GKOS 10 years ago would be worth a substantial amount today, underscoring the company's long‑term growth. These stories highlight both the current price action and the company's historical performance.